NanoLogix Adds Noted Journalist Bill Scanlon to Provide Media Relations
March 23 2009 - 9:28AM
PR Newswire (US)
HUBBARD, Ohio, March 23 /PRNewswire-FirstCall/ -- NanoLogix
(OTC:NNLX) announces that veteran journalist Bill Scanlon has
joined the company to coordinate publicity in advance of major
news. Scanlon's addition to the staff marks a significant evolution
in the company's information flow to investors and media, and will
aid in the introduction of the public to NanoLogix products. Bill
Scanlon brings 25 years of experience in science, medical and
business writing to NanoLogix, including articles about rapid
bio-detection. For the past 18 years, he worked at the Rocky
Mountain News, until its closing last month. Among his numerous
journalism honors are awards for articles about particle physics,
politics, ultra-athletics, and medical transplants. His series on a
hospital cover-up recently won the Associated Press's annual First
Amendment Award. Bret T. Barnhizer, CEO stated: "We are fortunate
to have obtained Bill Scanlon's services. His addition comes at a
time when key elements of our business plan are converging.
Enhanced public relations will bring awareness of the capabilities
of our BNP(TM) test kit technology as we move the company from pure
R&D and into production." About NanoLogix NanoLogix is a
biotechnology company focused primarily on medical diagnostics. Its
products offer accelerated detection and identification of
microorganisms present in infectious and non-infectious human
diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer,
cystic fibrosis, anthrax, and plague. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing. Patents granted to NanoLogix can be used in the areas of
applied microbiology, soil microbiology and bioremediation,
microbial physiology, molecular biology, pharmacology,
pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and
bioreactor-based hydrogen generation." More information on
NanoLogix is available at: http://www.nanologixinc.com/ This press
release contains statements, which may constitute "forward-looking
statements" within the meaning of the Securities Act of 1933 and
the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
NanoLogix, Inc., and members of its management as well as the
assumptions on which such statements are based. Prospective
investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements. The Company
undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of
unanticipated events or changes to future operating results.
Contact: Investor Relations Carol Surrena Telephone: 330-534-0800
E-mail: DATASOURCE: NanoLogix CONTACT: Investor Relations, Carol
Surrena, +1-330-534-0800, Web Site: http://www.nanologixinc.com/
Copyright